Loading...

APC anti-human CD4 Antibody

Pricing & Availability
Clone
RPA-T4 (See other available formats)
Regulatory Status
RUO
Workshop
IV T114
Other Names
T4
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
See APC spectral data
Cat # Size Price Quantity Check Availability Save
300514 100 tests 58€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
300552 100 µg 63€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
300537 500 tests 229€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD4, also known as T4, is a 55 kD single-chain type I transmembrane glycoprotein expressed on most thymocytes, a subset of T cells, and monocytes/macrophages. CD4, a member of the Ig superfamily, recognizes antigens associated with MHC class II molecules, and participates in cell-cell interactions, thymic differentiation, and signal transduction. CD4 acts as a primary receptor for HIV, binding to HIV gp120. CD4 has also been shown to interact with IL-16.

Product Details
Technical data sheet

Product Details

Reactivity
Human
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
µg size: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
test sizes: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
µg sizes: 0.2 mg/mL
test sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The CD4 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining using the µg size, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application. For flow cytometric staining using the test sizes, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Excitation Laser
Red Laser (633 nm)
Application Notes

The RPA-T4 antibody binds to the D1 domain of CD4 (CDR1 and CDR3 epitopes) and can block HIV gp120 binding and inhibit syncytia formation. Additional reported applications (for the relevant formats) include: immunohistochemistry of acetone-fixed frozen sections3,4,5, blocking of T cell activation1,2, and spatial biology (IBEX)10,11.  This clone was tested in-house and does not work on formalin fixed paraffin-embedded (FFPE) tissue. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 300569 - 300574).

Application References

(PubMed link indicates BioLegend citation)
  1. Knapp W, et al. 1989. Leucocyte Typing IV. Oxford University Press. New York. (Activ)
  2. Moir S, et al. 1999. J. Virol. 73:7972. (Activ)
  3. Deng MC, et al. 1995. Circulation 91:1647. (IHC)
  4. Friedman T, et al. 1999. J. Immunol. 162:5256. (IHC)
  5. Mack CL, et al. 2004. Pediatr. Res. 56:79. (IHC)
  6. Lan RY, et al. 2006. Hepatology 43:729.
  7. Zenaro E, et al. 2009. J. Leukoc. Biol. 86:1393. (FC) PubMed
  8. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
  9. Stoeckius M, et al. 2017. Nat. Methods. 14:865. (PG)
  10. Radtke AJ, et al. 2020. Proc Natl Acad Sci USA. 117:33455-33465. (SB) PubMed
  11. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Tang-Huau TL, et al. 2018. Nat Commun. 9:2570. PubMed
  2. Idorn M, et al. 2018. Oncoimmunology. 7:e1412029. PubMed
  3. Wang F, et al. 2018. Oncogenesis. 7:41. PubMed
  4. Eri Yamada et al. 2018. Cell host & microbe. 23(1):110-120 . PubMed
  5. Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed
  6. Schmidleithner L et al. 2019. Immunity. 50(5):1232-1248 . PubMed
  7. Tang M, et al. 2019. Biomed Res Int. 2019:1050285. PubMed
  8. Park MJ, et al. 2019. J Immunol. 203:127. PubMed
  9. Souriant S, et al. 2019. Cell Rep. 26:3586. PubMed
  10. Beyer AI, et al. 2017. Stem Cells Dev. 26:102. PubMed
  11. Martin GE, et al. 2018. Front Immunol. 1.019444444. PubMed
  12. Lundy SK, et al. 2018. Front Med (Lausanne). 0.38125. PubMed
  13. Li B, et al. 2019. Oncogenesis. 8:17. PubMed
  14. Kacherovsky N, et al. 2019. Nat Biomed Eng. 0.66875. PubMed
  15. Carpenter RS, et al. 2019. Sci Rep. 9:19105. PubMed
  16. Iwata A, et al. 2017. Nat Immunol. 18:563. PubMed
  17. Nakano Y, et al. 2017. PLoS Pathog. 13:e1006348. PubMed
  18. Cui J, et al. 2019. Neuro Oncol. 21:1436. PubMed
  19. Stuart T, et al. 2019. Cell. 177:1888. PubMed
  20. André M, et al. 2010. J Immunol. 185:2710. PubMed
  21. Koelsch K, et al. 2013. PLoS One. 8:50068. PubMed
  22. Reichwald K, et al. 2014. PLoS One. 9:105627. PubMed
  23. Fletcher H, et al. 2016. Nat Commun. 7: 11290. PubMed
  24. Usero L, et al. 2016. Diabetes. 65: 2356 - 2366. PubMed
  25. Kerstein A, et al. 2016. J Autoimmun. S0896-8411(16)30186-X. PubMed
  26. Koh WH, et al. 2020. STAR Protoc. 1:100203. PubMed
  27. Dyson MR, et al. 2020. MAbs. 12:1829335. PubMed
  28. Penkava F, et al. 2020. Nat Commun. 3.76875. PubMed
  29. Kim D, et al. 2020. Nat Med. 26:236. PubMed
  30. Huang LJ, et al. 2021. Immunity. 54(8):1728-1744.e7. PubMed
  31. Kobayashi Y, et al. 2020. Int J Oncol. 999:56. PubMed
  32. Chulpanova DS, et al. 2021. Biology (Basel). 10:. PubMed
  33. Lu Y, et al. 2021. Gastroenterology. 161:575. PubMed
  34. Park JA, et al. 2021. J Hematol Oncol. 14:142. PubMed
  35. Olety B, et al. 2021. Sci Adv. 7:eabj7398. PubMed
  36. Martín Monreal MT, et al. 2021. Front Immunol. 12:716250. PubMed
  37. Huber JE, et al. 2020. J Immunol. 204:1101. PubMed
  38. Gludish DW, et al. 2020. Sci Rep. 10:19900. PubMed
  39. Eleftheriadis T, et al. 2021. Int J Mol Sci. 22:. PubMed
  40. Pawlicki JM, et al. 2021. Cancer Res. 81:3241. PubMed
  41. Chang XL, et al. 2021. Nat Commun. 12:3343. PubMed
  42. Zuccato C, et al. 2022. Ther Adv Hematol. 13:20406207221100648. PubMed
  43. Ma S, et al. 2022. Nat Commun. 13:4118. PubMed
  44. Vyborova A, et al. 2022. Front Immunol. 13:915366. PubMed
  45. Lotfi S, et al. 2020. Retrovirology. 17:20. PubMed
  46. O'Leary CE, et al. 2021. Curr Protoc. 1:e77. PubMed
  47. Jancewicz I, et al. 2021. Cancers (Basel). 13:. PubMed
  48. Ng CY, et al. 2022. EMBO Rep. 23:e54271. PubMed
  49. Kim ST, et al. 2022. Nat Commun. 13:1970. PubMed
  50. Ng CY, et al. 2022. EMBO Rep. 23:e55871. PubMed
  51. Cao B, et al. 2022. Nat Commun. 13:6203. PubMed
  52. Lehmkuhl P, et al. 2021. Cell Mol Immunol. 18:1677. PubMed
  53. Yuan H, et al. 2022. J Clin Exp Hematop. 62:52. PubMed
  54. Hong Y, et al. 2022. J Leukoc Biol. 112:425. PubMed
  55. Vazquez-Lombardi R, et al. 2022. Immunity. 55:1953. PubMed
  56. Zhang Y, et al. 2022. J Immunol Res. 2022:9003902. PubMed
  57. Ogura H, et al. 2022. Nat Commun. 13:7063. PubMed
  58. Donadei C, et al. 2023. J Clin Med. 12:. PubMed
RRID
AB_314082 (BioLegend Cat. No. 300514)
AB_2564153 (BioLegend Cat. No. 300552)
AB_2562051 (BioLegend Cat. No. 300537)

Antigen Details

Structure
Ig superfamily, type I transmembrane glycoprotein, 55 kD
Distribution

T cell subset, majority of thymocytes, monocytes/macrophages

Function
MHC class II co-receptor, lymphocyte adhesion, thymic differentiation, HIV receptor
Ligand/Receptor
MHC class II molecules, HIV gp120, IL-16
Cell Type
Dendritic cells, Macrophages, Monocytes, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Center D, et al. 1996. Immunol. Today 17:476.
2. Gaubin M, et al. 1996. Eur. J. Clin. Chem. Clin. Biochem. 34:723.

Gene ID
920 View all products for this Gene ID
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.
Go To Top Version: 3    Revision Date: 12.11.2023

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account